155 related articles for article (PubMed ID: 33517536)
1. Rivaroxaban in Recurrent Ischemic Stroke Due to Protein S Deficiency: A Case Report.
Naghavi S; Pourmohammadi A; Adibi I
Neurol Ther; 2021 Jun; 10(1):401-406. PubMed ID: 33517536
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
3. Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment.
Undas A; Góralczyk T
Adv Clin Exp Med; 2016; 25(6):1321-1330. PubMed ID: 28028988
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
6. Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients.
Undas A; Goralczyk T
Blood Coagul Fibrinolysis; 2017 Sep; 28(6):438-442. PubMed ID: 28079536
[TBL] [Abstract][Full Text] [Related]
7. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
[TBL] [Abstract][Full Text] [Related]
9. Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
Ashley J; McArthur E; Bota S; Harel Z; Battistella M; Molnar AO; Jun M; Badve SV; Garg AX; Manuel D; Tanuseputro P; Wells P; Mavrakanas T; Rhodes E; Sood MM
Am J Kidney Dis; 2020 Sep; 76(3):311-320. PubMed ID: 32333946
[TBL] [Abstract][Full Text] [Related]
10. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Marik PE; Cavallazzi R
PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
[TBL] [Abstract][Full Text] [Related]
12. Recurrent venous thrombosis during direct oral anticoagulant therapy in a patient with protein S deficiency.
Yagi S; Kagawa K; Fujimoto E; Sata M
J Med Invest; 2019; 66(1.2):182-184. PubMed ID: 31064935
[TBL] [Abstract][Full Text] [Related]
13. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Schaefer JK; McBane RD; Black DF; Williams LN; Moder KG; Wysokinski WE
Thromb Haemost; 2014 Nov; 112(5):947-50. PubMed ID: 25118790
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban in the cardiovascular world: a direct anticoagulant useful to prevent stroke and venous and arterial thromboembolism.
Seoane L; Cortés M; Aris Cancela ME; Furmento J; Baranchuk A; Conde D
Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):501-514. PubMed ID: 29862875
[TBL] [Abstract][Full Text] [Related]
15. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Malec K; Góralczyk T; Undas A
Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
[TBL] [Abstract][Full Text] [Related]
16. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism.
Bryk AH; Piróg M; Plens K; Undas A
Vascul Pharmacol; 2016 Dec; 87():242-247. PubMed ID: 27865826
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
Kalani C; Awudi E; Alexander T; Udeani G; Surani S
Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
[No Abstract] [Full Text] [Related]
18. Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency.
Ameku K; Higa M
Case Rep Hematol; 2018; 2018():5217301. PubMed ID: 29607227
[TBL] [Abstract][Full Text] [Related]
19. The use of direct oral anticoagulants in inherited thrombophilia.
Skelley JW; White CW; Thomason AR
J Thromb Thrombolysis; 2017 Jan; 43(1):24-30. PubMed ID: 27734187
[TBL] [Abstract][Full Text] [Related]
20. An update on the pharmaceutical management of thrombosis.
Cosmi B
Expert Opin Pharmacother; 2016 Nov; 17(16):2149-2164. PubMed ID: 27685458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]